Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.
Bruton’s tyrosine kinase inhibitor
chidamide
chimeric antigen receptor T cell
diffuse large B-cell lymphoma
histone deacetylase inhibitor
zanubrutinib
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
03
2022
accepted:
16
05
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
Failure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. There is no consensus on the treatment for these patients and treatment remains empirical. We reported a case of an elderly R/R DLBCL patient who had We report the first successful case of dual inhibition of HDAC and BTK for the treatment of R/R DLBCL after failure to CAR-T cell therapy, which opens a new therapeutic possibility for the future.
Sections du résumé
Background
Failure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. There is no consensus on the treatment for these patients and treatment remains empirical.
Case Report
We reported a case of an elderly R/R DLBCL patient who had
Conclusion
We report the first successful case of dual inhibition of HDAC and BTK for the treatment of R/R DLBCL after failure to CAR-T cell therapy, which opens a new therapeutic possibility for the future.
Identifiants
pubmed: 35757723
doi: 10.3389/fimmu.2022.894787
pmc: PMC9226330
doi:
Substances chimiques
Antigens, CD19
0
Receptors, Chimeric Antigen
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
894787Informations de copyright
Copyright © 2022 Zhu, Tao, Miao, Liu and Yuan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncogene. 2017 Mar 30;36(13):1804-1815
pubmed: 27721407
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Clin Cancer Res. 2021 Jan 15;27(2):473-484
pubmed: 33028589
J Int Med Res. 2020 Jul;48(7):300060520936053
pubmed: 32643971
JCI Insight. 2017 Mar 23;2(6):e90196
pubmed: 28352655
J Hematol Oncol. 2020 May 11;13(1):48
pubmed: 32393328
Br J Haematol. 2017 Aug;178(3):434-441
pubmed: 28440559
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Curr Treat Options Oncol. 2021 Oct 26;22(12):112
pubmed: 34697650
Blood. 2016 Dec 29;128(26):3101-3112
pubmed: 27756747
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
J Hematol Oncol. 2017 Mar 15;10(1):69
pubmed: 28298231
Cancers (Basel). 2018 Jun 14;10(6):
pubmed: 29904021
J Exp Clin Cancer Res. 2019 Feb 18;38(1):86
pubmed: 30777096
Clin Cancer Res. 2016 Jun 1;22(11):2684-96
pubmed: 26819453
Nat Med. 2015 Aug;21(8):922-6
pubmed: 26193343
J Immunother Cancer. 2014 Apr 15;2:8
pubmed: 25054063
Cancer Res. 2016 Dec 1;76(23):6975-6987
pubmed: 27733371
Cancer Immunol Immunother. 2019 Dec;68(12):2081-2094
pubmed: 31720815
Blood Adv. 2022 Mar 22;6(6):1629-1636
pubmed: 34638136
Hematol Oncol. 2022 Feb 14;:
pubmed: 35165928
Clin Cancer Res. 2017 Jun 15;23(12):3084-3096
pubmed: 27993968
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
Immunotherapy. 2019 Mar;11(4):265-272
pubmed: 30606076
J Hematol Oncol. 2021 Oct 14;14(1):167
pubmed: 34649571
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Lancet Oncol. 2021 Oct;22(10):1403-1415
pubmed: 34516954
Blood. 2021 Apr 1;137(13):1832-1835
pubmed: 33156925